Repligen (NASDAQ:RGEN) Releases Earnings Results, Beats Estimates By $0.06 EPS

Repligen (NASDAQ:RGEN) issued its earnings results on Thursday. The biotechnology company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06, Briefing.com reports. The firm had revenue of $70.70 million during the quarter, compared to the consensus estimate of $65.47 million. Repligen had a net margin of 11.42% and a return on equity of 7.66%. The company’s revenue was up 48.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.14 earnings per share. Repligen updated its FY19 guidance to $0.94-0.98 EPS.

NASDAQ RGEN traded down $4.90 during trading hours on Friday, hitting $90.61. The company had a trading volume of 1,491,723 shares, compared to its average volume of 636,756. The company has a current ratio of 2.18, a quick ratio of 1.84 and a debt-to-equity ratio of 0.03. Repligen has a 1-year low of $47.23 and a 1-year high of $99.25. The stock has a market cap of $4.51 billion, a P/E ratio of 124.12, a PEG ratio of 5.74 and a beta of 1.08. The firm has a 50 day moving average of $85.77.

A number of equities analysts recently commented on RGEN shares. Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating and set a $102.00 target price for the company in a research note on Thursday, July 18th. HC Wainwright upgraded shares of Repligen from a “neutral” rating to a “buy” rating and set a $110.00 target price for the company in a research note on Monday, July 22nd. ValuEngine downgraded shares of Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, BidaskClub upgraded shares of Repligen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 27th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $94.00.

In other Repligen news, Director Karen A. Dawes sold 1,295 shares of the company’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $77.35, for a total value of $100,168.25. Following the completion of the transaction, the director now owns 118,329 shares in the company, valued at $9,152,748.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Glenn L. Md Cooper sold 5,000 shares of the company’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the completion of the transaction, the director now owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Chicago Equity Partners LLC boosted its stake in shares of Repligen by 19.3% during the second quarter. Chicago Equity Partners LLC now owns 33,695 shares of the biotechnology company’s stock worth $2,896,000 after buying an additional 5,445 shares during the period. Conestoga Capital Advisors LLC raised its holdings in Repligen by 3.7% during the second quarter. Conestoga Capital Advisors LLC now owns 1,698,329 shares of the biotechnology company’s stock worth $145,971,000 after purchasing an additional 60,899 shares in the last quarter. Swiss National Bank raised its holdings in Repligen by 8.2% during the second quarter. Swiss National Bank now owns 73,500 shares of the biotechnology company’s stock worth $6,317,000 after purchasing an additional 5,600 shares in the last quarter. Comerica Bank raised its holdings in Repligen by 0.7% during the second quarter. Comerica Bank now owns 76,955 shares of the biotechnology company’s stock worth $6,711,000 after purchasing an additional 560 shares in the last quarter. Finally, Stephens Inc. AR raised its holdings in Repligen by 10.4% during the second quarter. Stephens Inc. AR now owns 54,865 shares of the biotechnology company’s stock worth $4,716,000 after purchasing an additional 5,159 shares in the last quarter. Institutional investors own 85.56% of the company’s stock.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: What are the benefits of investing in REITs?

Earnings History for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.